 Merck & Co. said on Monday it learned the results of a long-running clinical trial designed to answer questions about the efficacy of blockbuster cholesterol drugs Vytorin and Zetia and determined there is no need to write down their value for accounting purposes.. Merck hasn’t disclosed the outcome of the patient study, but the accounting disclosure in a regulatory filing suggests Merck doesn’t expect the results to significantly diminish the remaining value of the drugs, which may begin facing generic competition in the...
  